RAPS on delayed Brexit
The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals.
In an attempt to find a way forward - or perhaps the exit! - in Brexit negotiations, Prime Minister Theresa May has now secured an extension to the 29 March deadline. Paul Brooks, Executive Director, RAPS, comments on recent proceedings.
"Now that Prime Minister Theresa May’s request for a Brexit deadline extension has been granted, it will provide time to make needed preparations. Uncertainty about what will happen after the UK leaves the European Union has been a major concern for regulatory affairs professionals working in pharmaceutical and medical device companies since the day the result of the Brexit referendum was announced in 2016.
"Regulatory professionals provide strategies and guidance to ensure needed healthcare products continue to flow into healthcare systems and are available to patients across Europe. Clarity on how the post-Brexit EU regulatory system and a newly separate UK system will operate relative to one another is urgently needed. Regulatory strategies responding to any change take significant time and resources to implement and need to continuously address clear regulator expectations.
"Unfortunately, now more than 2 years later, many important details remain unclear. Taking additional time to hammer out important points and possibly get a deal in place can only help, but it will be critical to use the extra time productively. In the end, if UK and EU regulations, processes and procedures diverge significantly, or if the two sides fail to agree on some form of mutual recognition, it could lead to duplication of regulatory efforts, most likely resulting in increased costs, time and resourcing for manufacturers, and possibly threatening the availability of current life-saving medicines and medical technology for healthcare providers and patients, as well slowing down access to enhanced or innovative solutions.
"The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals who must guide and advise companies wishing to preserve access to such products. It is one of the major topics we will be examining at the upcoming RAPS Regulatory Conference – Europe 2019, this May in Brussels with separate sessions regarding pharmaceuticals and devices in the post-Brexit era."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance